Confluence Launches CRISPR Cancer-Killing Platform
Confluence Genetics launched Cas-CLEAR, a CRISPR-based therapeutic platform that employs Cas12a2 nucleases to recognize cancer-specific genetic signatures and, upon target recognition, trigger broad collateral cleavage of cellular DNA and RNA — selectively killing cells…
